Oxytocin, a Novel Treatment for Methamphetamine Use Disorder
Open accessAbstract
The treatment of substance abuse with oxytocin is a novel approach to a challenging public health issue that continues to contribute to a growing economic cost for societies worldwide. Methamphetamine addiction is one of the leading causes of mortality worldwide, and despite advances in understanding the neurobiology of methamphetamine addiction, treatment options are limited. There are no medications that the Food and Drug Administration currently approves for stimulant use disorder. Off-label use of therapies for stimulant misuse include antidepressants, anxiolytics, and milder stimulants as replacement agents. Due to the shortcomings of these attempts to treat a complicated psychiatric disorder, recent attention to oxytocin therapy (OT) has gained momentum in clinical studies as a possible therapy in the context of social stress, social anxiety, social cognition, and psychosis. Oxytocin produces enhanced connectivity between cortical regions. The results from studies in rodents with OT suggest that central neuromodulation of oxytocin may be beneficial across transition states of stimulant dependence and may alleviate intense withdrawal symptoms. Studies of oxytocin in the context of other drugs of abuse, including cocaine, cannabis, and alcohol, also support the potential of oxytocin to treat stimulant use disorder, methamphetamine type. Methamphetamine abuse continues to be a significant cause of distress and dysfunction throughout the world. The effects of oxytocin on methamphetamine use outlined in this review should act as a catalyst for further investigation into the efficacy of treating stimulant use disorder, methamphetamine type with oxytocin in humans. More human-based research should initiate studies involving the long-term efficacy, side effects, and patient selection.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are currently no approved pharmacotherapies for MAUD despite extensive research.
“Demand for treatment is increasing globally [4]; however, there are currently no approved pharmacotherapies, despite extensive research investigating potential candidates [6][7][8].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089 · cited 1× · see citing works
“A portion of oxytocin is released centrally from the PVN and SON to act on receptors throughout the brain, including portions of the cortex, olfactory system, basal ganglia, limbic system, and brainstem [39,41,42].”
BackgroundSignal transduction by the lipopolysaccharide receptor, Toll-like receptor-4
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01976.x · Cited by 1,254 · cited 1× · see citing works
“The TLR4 signaling pathway is a well-studied component of the innate immune system’s proinflammatory cytokines and chemokines [30].”
BackgroundEvoked axonal oxytocin release in the central amygdala attenuates fear response
Knobloch, H. S., Charlet, A., Hoffmann, L. C., Eliava, M., Khrulev, S., Cetin, A. H., Osten, P., Schwarz, M. K., Seeburg, P. H., Stoop, R., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.030 · Cited by 1,049 · cited 1× · see citing works
“Oxytocin has been linked to various physiological processes related to drug addiction, including the hypothalamic-pituitary-adrenal axis stress response, the central amygdala relating to anxiety and fear, and antinociception, autonomic regulation via the brainstem [43,44].”
BackgroundOxytocin: The Great Facilitator of Life
Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037 · cited 1× · see citing works
“A portion of oxytocin is released centrally from the PVN and SON to act on receptors throughout the brain, including portions of the cortex, olfactory system, basal ganglia, limbic system, and brainstem [39,41,42].”
BackgroundStriatal dopamine nerve terminal markers in human, chronic methamphetamine users
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G. D., Anthony, R. M., Schmunk, G. A., Shannak, K. S., Haycock, J. W., & Kish, S. J. (1996) · Nature Medicine · doi:10.1038/nm0696-699 · Cited by 718 · cited 1× · see citing works
“Long-term methamphetamine abusers have been found to have reduced striatal dopamine levels [31].”
BackgroundNeurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 669 · see citing works
Yoshida, M., Takayanagi, Y., Inoue, K., Kimura, T., Young, L. J., Onaka, T., & Nishimori, K. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5593-08.2009 · Cited by 608 · cited 2× · see citing works
“Extensive evidence now supports oxytocin’s role in the complex physiology of addiction and the attenuation of anxiety, inflammatory, and stress responses [39,40].”
BackgroundMethamphetamine toxicity and messengers of death
Krasnova, I. N., & Cadet, J. L. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.03.002 · Cited by 589 · cited 3× · see citing works
“These mechanisms of dopamine-induced neurotoxicity and inflammation cause disruption of endogenous dopamine signaling by destroying post-synaptic neurons and dopamine terminals [26].”
BackgroundThe need for speed: an update on methamphetamine addiction
Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 442 · cited 1× · see citing works
“Methamphetamine works through various mechanisms to increase the availability of catecholamine neurotransmitters, including dopamine and norepinephrine, in nerve terminals in the central nervous system (CNS) and peripheral nervous system (PNS) [13].”
BackgroundStructural and metabolic brain changes in the striatum associated with methamphetamine abuse
Chang, L., Alicata, D., Ernst, T. M., & Volkow, N. D. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01782.x · Cited by 431 · cited 1× · see citing works
“Prominent changes include decreased hippocampal sizes, enlarged striatum, and loss of grey matter in cingulate and limbic cortices [33,34].”
BackgroundEliava, M., Melchior, M., Knobloch-Bollmann, H. S., Wahis, J., da Silva Gouveia, M., Tang, Y., Ciobanu, A. C., Triana del Rio, R., Roth, L. C., Althammer, F., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.041 · Cited by 409 · see citing works
Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review
Paulus, M. P., & Stewart, J. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0246 · Cited by 310 · cited 3× · see citing works
“Recent data from the National Survey on Drug Use and Health (NSDUH) regarding methamphetamine use in the USA concluded that the number of people with stimulant use disorder methamphetamine type was 1,048,000 in 2019 [12].”
BackgroundCallaghan, R. C., Cunningham, J. K., Sykes, J. R., & Kish, S. J. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.013 · Cited by 272 · see citing works
Methamphetamine: Effects on the brain, gut and immune system
Prakash, M. D., Tangalakis, K., Antonipillai, J., Stojanovska, L., Nurgali, K., & Apostolopoulos, V. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.009 · Cited by 220 · cited 1× · see citing works
“The result of increased availability and decreased metabolism is a massive abundance of catecholamines released in synaptic clefts, which can produce a variety of physiologic consequences including addiction, psychiatric changes, neurologic damage, cardiovascular damage, and gastrointestinal damage [19].”
BackgroundNeuropathology of substance use disorders
Cadet, J. L., Bisagno, V., & Milroy, C. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1221-7 · Cited by 207 · cited 1× · see citing works
“Multiple studies have linked long-term methamphetamine use to alterations of brain structure and biochemistry [20].”
BackgroundQuirin, M., Kuhl, J., & Düsing, R. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.12.005 · Cited by 204 · cited 1× · see citing works
“Extensive evidence now supports oxytocin’s role in the complex physiology of addiction and the attenuation of anxiety, inflammatory, and stress responses [39,40].”
BackgroundStimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy
Ciccarone, D. (2011) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2010.11.004 · Cited by 200 · cited 3× · see citing works
“However, most of these studies have been limited to small clinical trials, and there are currently non-FDA-approved medications to treat cocaine or methamphetamine addiction [4,35].”
BackgroundPharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194 · cited 4× · see citing works
“However, most of these studies have been limited to small clinical trials, and there are currently non-FDA-approved medications to treat cocaine or methamphetamine addiction [4,35].”
BackgroundInfluentialWill the Methamphetamine Problem Go Away?
Rawson, R. A., Anglin, M. D., & Ling, W. W. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v21n01_02 · Cited by 193 · cited 1× · see citing works
“The use of the drug soared in the 1990s, mainly in the midwestern and western parts of the USA, eventually reaching epidemic status in the early 2000s [9].”
BackgroundNeurologic Manifestations of Chronic Methamphetamine Abuse
Rusyniak, D. E. (2013) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2013.02.005 · Cited by 162 · see citing works
Methamphetamine Rapidly Decreases Vesicular Dopamine Uptake
Brown, J. M., Hanson, G. R., & Fleckenstein, A. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742221.x · Cited by 158 · cited 2× · see citing works
“Following the release, cytosolic dopamine concentrations remain high because amphetamines also interfere with the vesicular reuptake of the catecholamine via VMAT2 [17].”
BackgroundWhy is parkinsonism not a feature of human methamphetamine users?
Moszczyńska, A., Fitzmaurice, P. S., Ang, L. C., Kalasinsky, K. S., Schmunk, G. A., Peretti, F. J., Aiken, S. S., Wickham, D. J., & Kish, S. J. (2004) · Brain · doi:10.1093/brain/awh046 · Cited by 152 · cited 1× · see citing works
“A further study concluded that the dopamine levels in the putamen were as severely diminished as liken to people with Parkinson’s disease [32].”
BackgroundAmphetamine-induced Dopamine Efflux
Khoshbouei, H., Wang, H.-W., Lechleiter, J. D., Javitch, J., & Galli, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212815200 · Cited by 151 · see citing works
Qi, J., Yang, J., Wang, F., Zhao, Y., Song, M., & Wu, C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.010 · Cited by 149 · cited 10× · see citing works
“Unsurprisingly, methamphetamine exposure resulted in a strong conditioned place preference not observed in the saline groups [57].”
BackgroundMethodInfluentialCarson, D. S., Cornish, J. L., Guastella, A. J., Hunt, G. E., & McGregor, I. S. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.018 · Cited by 146 · cited 9× · see citing works
“Following this initial experiment, an additional experiment was devised to analyze the effects of oxytocin on methamphetamine-induced hyperactivity on drug-naïve rat models to account for potential confounds resulting from the diminished operant conditioning observed in the treatment arm [49].”
BackgroundMethodResultInfluentialBrown, J. M., Hanson, G. R., & Fleckenstein, A. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38814-7 · Cited by 135 · cited 1× · see citing works
“Amphetamines, including methamphetamine, act as substrates for the plasmalemma dopamine transporter (DAT), allowing admittance into dopaminergic pre-synaptic terminals [14,15].”
BackgroundEffect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys
Moore, R. J., Vinsant, S. L., Nader, M. A., Porrino, L. J., & Friedman, D. P. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199809)30:1 · Cited by 134 · see citing works
Moszczyńska, A., & Callan, S. P. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.238501 · Cited by 133 · cited 1× · see citing works
“The possible mechanisms of methamphetamine-induced brain changes are neurotoxicity and inflammation [25].”
BackgroundCarson, D. S., Hunt, G. E., Guastella, A. J., Barber, L., Cornish, J. L., Arnold, J. C., Boucher, A. A., & McGregor, I. S. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00247.x · Cited by 127 · cited 9× · see citing works
“The treatment group was administered oxytocin before methamphetamine administration [51].”
BackgroundMethodResultInfluentialA brief history of oxytocin and its role in modulating psychostimulant effects
Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105 · cited 1× · see citing works
“Recent studies in rodents and humans suggest that OT may modulate substance-induced behaviors in the context of methamphetamine and cocaine use and even enhance prosocial behavioral responses to 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) [38].”
BackgroundBaracz, S. J., Rourke, P. I., Pardey, M. C., Hunt, G. E., McGregor, I. S., & Cornish, J. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.11.038 · Cited by 98 · cited 8× · see citing works
“The hypothalamic PVN houses oxytocinergic projections that terminate in the NAc and other addiction-associated areas of the brain [47].”
BackgroundInfluentialOxytocin Acts in Nucleus Accumbens to Attenuate Methamphetamine Seeking and Demand
Cox, B. M., Bentzley, B. S., Regen-Tuero, H. C., See, R. E., Reichel, C. M., & Aston‐Jones, G. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.11.011 · Cited by 98 · cited 9× · see citing works
“The hypothalamic PVN houses oxytocinergic projections that terminate in the NAc and other addiction-associated areas of the brain [47].”
BackgroundInfluentialTargeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
Lee, M. R., Rohn, M. C. H., Tanda, G., & Leggio, L. (2016) · CNS Drugs · doi:10.1007/s40263-016-0313-z · Cited by 97 · cited 5× · see citing works
“For this reason, central neuromodulation of oxytocin pathways through activation of a variety of glutamate and dopamine receptors, among other mechanisms, may reliably alleviate specific symptoms of methamphetamine withdrawal [7].”
BackgroundInfluentialWang, X., Northcutt, A. L., Cochran, T. A., Zhang, X., Fabisiak, T., Haas, M. E., Amat, J., Li, H., Rice, K. C., Maier, S. F., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00225 · Cited by 94 · cited 5× · see citing works
“The TLR4 signaling pathway is a well-studied component of the innate immune system’s proinflammatory cytokines and chemokines [30].”
BackgroundInfluentialRebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction
Bowen, M. T., & Neumann, I. D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.003 · Cited by 83 · cited 2× · see citing works
“Even more so, oxytocin has also been shown to enhance connectivity between frontal and other cortical regions [8].”
BackgroundMethamphetamine: Here we go again?
Maxwell, J. C., & Brecht, M. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.07.017 · Cited by 71 · see citing works
Oxytocin and Rodent Models of Addiction
Leong, K.-C., Cox, S. S., King, C. E., Becker, H. C., & Reichel, C. M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.007 · Cited by 69 · cited 1× · see citing works
“Administration of oxytocin reduces both the consumption of substances of abuse (SOA) and reward consequences while also decreasing some of the intoxicating effects of SOA in rodent studies [45,48,49].”
BackgroundPotashkin, J., & Meredith, G. E. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.144 · Cited by 65 · cited 1× · see citing works
“Subsequent oxidative stress leads to significant dysfunction of neurons, terminal degeneration, and apoptosis [27].”
BackgroundInhibition of monoamine oxidase by d-methamphetamine
Suzuki, O., Hattori, H., Asano, M., Oya, M., & Katsumata, Y. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90493-1 · Cited by 64 · cited 1× · see citing works
“Catecholamines are metabolized by the mitochondrial enzyme monoamine oxidase (MAO); methamphetamine interferes with MAO function to inhibit the metabolism of catecholamines [18].”
BackgroundDARK Classics in Chemical Neuroscience: Methamphetamine
Abbruscato, T. J., & Trippier, P. C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00123 · Cited by 55 · see citing works
Tata, D. Α., & Yamamoto, B. K. (2008) · Synapse · doi:10.1002/syn.20497 · Cited by 54 · cited 1× · see citing works
“Psychostimulants also cause excitotoxic damage by stimulating glutamate release [26,28].”
BackgroundFunctional and Structural Brain Changes Associated with Methamphetamine Abuse
Jan, R. K., Kydd, R. R., & Russell, B. R. (2012) · Brain Sciences · doi:10.3390/brainsci2040434 · Cited by 51 · cited 1× · see citing works
“Prominent changes include decreased hippocampal sizes, enlarged striatum, and loss of grey matter in cingulate and limbic cortices [33,34].”
BackgroundBaracz, S. J., Parker, L. M., Suraev, A. S., Everett, N. A., Goodchild, A. K., McGregor, I. S., & Cornish, J. L. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12337 · Cited by 50 · cited 18× · see citing works
“Following the acquisition of the conditioned response, the rats underwent an extinction period lasting a minimum of ten days [52].”
InfluentialStuart, A. M., Baker, A. L., Denham, A. M. J., Lee, N. K., Hall, A., Oldmeadow, C., Dunlop, A., Bowman, J., & McCarter, K. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.09.005 · Cited by 49 · cited 1× · see citing works
“no reliable evidence of any current pharmacologic agents that reduce psychological distress or physical symptoms associated with methamphetamine use [36].”
BackgroundEverett, N. A., Baracz, S. J., & Cornish, J. L. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0566-6 · Cited by 48 · see citing works
Murnane, K. S., Perrine, S. A., Finton, B. J., Galloway, M. P., Howell, L. L., & Fantegrossi, W. E. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2504-0 · Cited by 43 · see citing works
Self-citationOxytocin excites nucleus accumbens shell neurons in vivo
Moaddab, M., Hyland, B. I., & Brown, C. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.08.013 · Cited by 41 · cited 1× · see citing works
“The hypothalamic PVN houses oxytocinergic projections that terminate in the NAc and other addiction-associated areas of the brain [47].”
BackgroundBaracz, S. J., Everett, N. A., & Cornish, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136132 · Cited by 37 · see citing works
A potential role for N‐acetylcysteine in the management of methamphetamine dependence
McKetin, R., Dean, O. M., Baker, A., Carter, G. L., Turner, A., Kelly, P. J., & Berk, M. (2016) · Drug and Alcohol Review · doi:10.1111/dar.12414 · Cited by 30 · cited 1× · see citing works
“Furthermore, GABA enhancers, including topiramate, and more recently, N-acetylcysteine, have shown some marginal benefit and may be beneficial in reducing cravings and relapse prevention [35,37].”
BackgroundOxytocin and Addiction: Potential Glutamatergic Mechanisms
Sundar, M., Patel, D., Young, Z., & Leong, K.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052405 · Cited by 29 · cited 7× · see citing works
“Through restoring GFAP expression and, therefore, reversal of astrocyte function, OT may indirectly affect glutamatergic transmission opposing drug-induced behaviors [6].”
BackgroundInfluentialOxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges
Che, X., Cai, J., Liu, Y., Xu, T., Yang, J., & Wu, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107820 · Cited by 28 · cited 1× · see citing works
“Drug addiction is one of the leading causes of mortality worldwide, and despite advances in understanding the neurobiology of drug addiction, treatment options are severely limited [2].”
BackgroundSubiah, C. O., Mabandla, M. V., Phulukdaree, A., Chuturgoon, A. A., & Daniels, W. M. U. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9297-7 · Cited by 24 · cited 10× · see citing works
“devised a study to evaluate the effects of vasopressin and oxytocin on the mesolimbic system of rats following exposure to methamphetamine [50].”
BackgroundMethodInfluentialEverett, N. A., Baracz, S. J., & Cornish, J. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.06.002 · Cited by 23 · cited 11× · see citing works
“Additionally, after controlling for methamphetamine use, oxytocin enhancement resulted in small but significant differences in pathophysiological effects, namely lowered heart rates [55].”
BackgroundMethodInfluentialOxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial
Stauffer, C. S., Moschetto, J. M., McKernan, S. M., Meinzer, N. K., Chiang, C., Rapier, R., Hsiang, E., Norona, J. C., Borsari, B. E., & Woolley, J. D. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108059 · Cited by 21 · see citing works
Developing Treatments for Stimulant Abuse: A Brief Overview.
Davidson, C. (2016) · PubMed · Cited by 7 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [5]Oxytocin in the Socioemotional Brain: Implications for Psychiatric Disorders [Internet] Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734884/ (accessed on 20 November 2021)
Cited by
Sorted by citations
Florea, T., Palimariciuc, M., Cristofor, A. C., Dobrin, I., Chiriță, R., Bîrsan, M., Dobrin, R., & Pădurariu, M. (2022) · Medicina · doi:10.3390/medicina58070923 · Cited by 28 · see citing works
“More pre-clinical studies have evaluated the effects of oxytocin on central neuromodulation from transition states of methamphetamine dependence, alleviating intense withdrawal symptoms with promising results in rats [65].”
BackgroundExploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16 · see citing works
Self-citationTranscranial Stimulation for the Treatment of Stimulant Use Disorder
Edinoff, A. N., Sall, S., Roberts, T. D., Tomlinson, H., Soileau, L. G., Jackson, E. D., Murnane, K. S., Wenger, D. M., Cornett, E. M., Toms, J., et al. (2023) · Neurology International · doi:10.3390/neurolint15010021 · Cited by 12 · see citing works
“These advances have provided a greater opportunity for the future development of pharmacological interventions which could be used in conjunction with known effective behavioral therapies [23].”
BackgroundSelf-citationCarrico, A. W., Cherenack, E. M., Flentje, A., Moskowitz, J. T., Asam, K. R., Ghanooni, D., Chavez, J. V., Neilands, T. B., Dilworth, S. E., Rubin, L. H., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.05.025 · Cited by 11 · see citing works
Sharma, P., Sawaya, M. F., Dumitrescu, A. M., Kolluru, G. K., Schmoutz, C. D., Salinas, A. G., Cannon, C. E., Kumbhare, D., Korneeva, N. L., Vest, M. F., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00770 · Cited by 11 · see citing works
“…medications with anti-inflammatory or neuroprotective properties, investigating psychedelics (e.g., psilocybin) and ketamine for their potential to reset maladaptive neural circuits, and exploring personalized medicine approaches based on genetic and neurobiological profiles [53,291 – 293].”
Self-citationKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9 · see citing works
Does chronic use of amphetamine-type stimulants impair interference control? – A meta-analysis
Opitz, A., Petasch, M.-S., Klappauf, R., Kirschgens, J., Hinz, J. R., Dittmann, L., Dathe, A. S., Quednow, B. B., Beste, C., & Stock, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.105020 · Cited by 6 · see citing works
The Use of Oxytocin for the Treatment of Opioid Use Disorder
Edinoff, A. N., Sall, S., Honore, L. G., Dies, R., Zaheri, A. R., Kataria, S., Jackson, E. D., Shekoohi, S., Cornett, E. M., Murnane, K. S., et al. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01105-6 · Cited by 5 · see citing works
“More recently, oxytocin has been undergoing research on its involvement as a potential therapy for addiction, such as methamphetamine use [25].”
BackgroundSelf-citationLapka, M., Charalambous, C., Khryakova, A., Certilina, A., Novotný, J., Hejnová, L., & Šustková-Fišerová, M. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173528 · Cited by 4 · see citing works
Örüm, D., Örüm, M. H., Kapıcı, Y., & Abuş, S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06018-1 · Cited by 4 · see citing works
“Antidepressants and benzodiazepines are psychotropics frequently used in both conditions [21, 22].”
BackgroundAthota, P., Nguyen, N. M., Schaal, V. L., Sankarasubramanian, J., Guda, C., Yelamanchili, S. V., & Pendyala, G. (2023) · Viruses · doi:10.3390/v15091948 · Cited by 3 · see citing works
Arunogiri, S., Catchlove, S. J., Bove, E., McKetin, R., Manning, V., Bedi, G., & Lubman, D. I. (2024) · Research Square · doi:10.21203/rs.3.rs-4428433/v1
Online Narcotics Anonymous: An Option for Addressing Methamphetamine Use Disorder
Galanter, M. S., White, W. L., & Hunter, B. D. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001606
Jang, W., Song, S.-H., Son, T., Ryu, I. S., Jung, J. H., Lee, S., & Jeong, C. (2025) · Molecular Brain · doi:10.1186/s13041-025-01249-z
“Additionally, Oxt has been proposed as a therapeutic target for reducing drug-seeking behaviors and facilitating recovery [44, 45].”
Brett, J., Lea, T., Knock, E., Albert, S. M., Acheson, L. S., Siefried, K. J., & Job, S. (2025) · Addiction · doi:10.1111/add.70284
- Authors
- Edinoff, A. N., Thompson, E., Merriman, C. E., Alvarez, M. R., Alpaugh, E. S., Cornett, E. M., Murnane, K. S., Kozinn, R. L., Shah-Bruce, M., Kaye, A. M., & Kaye, A. D.
- Affiliations
- Louisiana State University (US)
- The University of Texas Southwestern Medical Center (US)
- University of the Pacific (US)
- Corresponding author
- Edinoff, Amber N.
- Venue
- Neurology International
- Publisher
- MDPI AG
- Published
- 2022-01-30
- Volume
- 14
- Issue
- 1
- Pages
- 186-198
- ISSN
- 2035-8377 (ISSN-L)
- PMC
- PMC8883935
- OpenAlex
- W4210434317
- Cited by
- 15
- References
- 55
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 5 · 2022: 2
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neurology International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Scholarly Commons (University of the Pacific) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- oxytocin, methamphetamine dependence, stimulant use disorder, pharmacotherapy, social stress, social anxiety, social cognition, psychosis, cortical connectivity, withdrawal symptoms, cocaine, cannabis, alcohol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
